Search Results - "Vistisen, K"

The effect of geriatric intervention in frail elderly patients receiving chemotherapy for colorectal cancer: a randomized trial (GERICO) by Lund, C M, Vistisen, K K, Dehlendorff, C, Rønholt, F, Johansen, J S, Nielsen, D L

“…Better surgical techniques, chemotherapy and biological therapy have improved survival in patients with colorectal cancer (CRC), most markedly in younger…”
Get full text

Geriatric assessment and intervention in older vulnerable patients undergoing surgery for colorectal cancer: a protocol for a randomised controlled trial (GEPOC trial) by Dolin, Troels G, Mikkelsen, Marta, Jakobsen, Henrik L, Nordentoft, Tyge, Pedersen, Trine S, Vinther, Anders, Zerahn, Bo, Vistisen, Kirsten K, Suetta, Charlotte, Nielsen, Dorte, Johansen, Julia S, Lund, Cecilia M

“…The incidence of colorectal cancer (CRC) increases with age. Older patients are a heterogeneous group ranging from fit to frail with various comorbidities…”
Get full text

Induction chemotherapy with capecitabine and oxaliplatin followed by chemoradiotherapy before total mesorectal excision in patients with locally advanced rectal cancer by Schou, J.V., Larsen, F.O., Rasch, L., Linnemann, D., Langhoff, J., Høgdall, E., Nielsen, D.L., Vistisen, K., Fromm, A., Jensen, B.V.

“…Preoperative chemoradiation in patients with locally advanced rectal cancer has no impact on overall survival (OS) and distant recurrences. The aim of the…”
Get full text

Randomised trial of cetuximab every 2 weeks with FOLFIRI or cetuximab with alternating FOLFIRI/FOLFOX in patients with RAS and BRAF wild type metastatic colorectal cancer: Nordic 8 results by Pfeiffer, P., Glimelius, B., Winther, S., Qvortrup, C., Yilmaz, M., Berglund, À, Vistisen, K., Kersten, C., Liposits, G., Sorbye, H.

Get full text

Efficacy and toxicity of adjuvant chemotherapy in elderly patients with colorectal cancer: the ACCORE study by Lund, C M, Nielsen, D, Dehlendorff, C, Christiansen, A B, Rønholt, F, Johansen, J S, Vistisen, K K

“…BackgroundElderly patients with primary colorectal cancer (CRC) are less frequently treated with adjuvant chemotherapy than younger patients due to concerns…”
Get full text

Dose-dependent inhibition of CYP1A2, CYP2C19 and CYP2D6 by citalopram, fluoxetine, fluvoxamine and paroxetine by JEPPESEN, U, GRAM, L. F, VISTISEN, K, LOFT, S, POULSEN, H. E, BRØSEN, K

“…The purpose of this pharmacokinetic study was to investigate the dose-dependent inhibition of model substrates for CYP2D6, CYP2C19 and CYP1A2 by four marketed…”
Get full text

Myocardial Ischemia Induced by 5‐Fluorouracil: A Prospective Electrocardiographic and Cardiac Biomarker Study by Dyhl‐Polk, Anne, Schou, Morten, Vistisen, Kirsten K., Sillesen, Anne‐Sophie, Serup‐Hansen, Eva, Faber, Jens, Klausen, Tobias W., Bojesen, Stig E., Vaage‐Nilsen, Merete, Nielsen, Dorte L.

“…Background Cardiotoxicity induced by 5‐fluorouracil (5‐FU) is well known but poorly understood. In this study, we undertook ECG recording (Holter) and analyses…”
Get full text

Age-dependent differences in first-line chemotherapy in patients with metastatic colorectal cancer: the DISCO study by Lund, Cecilia M, Vistisen, Kirsten K, Dehlendorff, Christian, Rønholt, Finn, Johansen, Julia S, Nielsen, Dorte L

“…First-line chemotherapy for metastatic colorectal cancer (mCRC) is effective and feasible in selected older patients. We investigated age-dependent differences…”
Get more information

Low CYP1A2 activity associated with testicular cancer by Vistisen, Kirsten, Loft, Steffen, Olsen, Jørgen H., Vallentin, Susanne, Ottesen, Svend, Hirsch, Fred R., Poulsen, Henrik E.

“…The incidence rate of testicular cancer has increased during the last 50 years. An interplay between changing environmental factors and individual…”
Get full text

Moclobemide, a substrate of CYP2C19 and an inhibitor of CYP2C19, CYP2D6, and CYP1A2: a panel study by Gram, L F, Guentert, T W, Grange, S, Vistisen, K, Brøsen, K

“…The reversible monoamine oxidase A inhibitor moclobemide was given in single (300 mg) and multiple doses (600 mg/day) to 11 male and four female healthy…”
Get more information

Single nucleotide polymorphisms and the risk of venous thrombosis: results from a Danish case‐cohort study by El‐Galaly, Tarec C., Severinsen, Marianne T., Overvad, Kim, Steffensen, Rudi, Vistisen, Anders K., Tjønneland, Anne, Kristensen, Søren R.

“…Summary A number of single nucleotide polymorphisms (SNP) have been linked to higher risk of venous thromboembolism (VTE). We investigated the VTE risk…”
Get full text

Capecitabine and Oxaliplatin Before, During, and After Radiotherapy for High-Risk Rectal Cancer by Larsen, Finn Ole, Markussen, Alice, Jensen, Benny V., Fromm, Anne L., Vistisen, Kirsten K., Parner, Vibeke K., Linnemann, Dorte, Hansen, Rasmus H., Johannesen, Helle H., Schou, Jakob V.

“…Treatment with capecitabine and oxaliplatin before, during, and after radiotherapy for high-risk rectal cancer is safe and feasible. It results in a good rate…”
Get full text

Effect of a multimodal high intensity exercise intervention in cancer patients undergoing chemotherapy: randomised controlled trial by Adamsen, Lis, Quist, Morten, Andersen, Christina, Møller, Tom, Herrstedt, Jørn, Kronborg, Dorte, Baadsgaard, Marie T, Vistisen, Kirsten, Midtgaard, Julie, Christiansen, Birgitte, Stage, Maria, Kronborg, Morten T, Rørth, Mikael

“…Objective To assess the effect of a multimodal group exercise intervention, as an adjunct to conventional care, on fatigue, physical capacity, general…”
Get full text

O-015Randomised trial of cetuximab every 2 weeks with FOLFIRI or cetuximab with alternating FOLFIRI/FOLFOX in patients with RAS and BRAF wild type metastatic colorectal cancer: Nordic 8 results by Pfeiffer, P, Glimelius, B, Winther, S, Qvortrup, C, Yilmaz, M, Berglund, À, Vistisen, K, Kersten, C, Liposits, G, Sorbye, H

Get full text

Effect of geriatric intervention on physical function in patients operated for colorectal cancer by Dolin, T.G., Madsen, K., Mikkelsen, M., Jakobsen, H., Nordentoft, T., Pedersen, T., Vinther, A., Zerahn, B., Vistisen, K., Suetta, C., Nielsen, D., Johansen, J., Lund, C.

Get full text

8-Hydroxydeoxyguanosine as a urinary biomarker of oxidative DNA damage by Loft, S, Fischer-Nielsen, A, Jeding, I B, Vistisen, K, Poulsen, H E

“…Living organisms are continuously exposed to reactive oxygen species as a consequence of biochemical reactions as well as external factors. Oxidative DNA…”
Get more information

Maintenance Therapy With Cetuximab Every Second Week in the First-Line Treatment of Metastatic Colorectal Cancer: The NORDIC-7.5 Study by the Nordic Colorectal Cancer Biomodulation Group by Pfeiffer, Per, Sorbye, Hafdan, Qvortrup, Camilla, Karlberg, Mia, Kersten, Christian, Vistisen, Kirsten, Lindh, Birgitta, Bjerregaard, Jon Kroll, Glimelius, Bengt

“…Micro-Abstract In the NORDIC-7.5 trial, cetuximab administered every 2 weeks in 152 patients with Kirsten rat sarcoma viral oncogene homolog wild type…”
Get full text

Persistence and Adherence to GLP-1 RA treatment in Type 2 Diabetes Mellitus: a Nationwide registry study by Lassen, M C H, Johansen, N D, Modin, D, Catarig, A M, Vistisen, B K, Amadid, H, Zimmermann, E, Gislason, G, Biering-Soerensen, T

“…Abstract Background The use of glucagon-like peptide-1 receptor agonsists (GLP-1 RA) continues to rise and is increasingly important in the treatment of type-2…”
Get full text

Maintenance therapy with biweekly cetuximab (C) in the first-line treatment of metastatic colorectal cancer (mCRC): The NORDIC 7.5 study (NCT00660582), by the Nordic Colorectal Cancer Biomodulation Group by Pfeiffer, Per, Sorbye, Halfdan, Qvortrup, Camilla, Karlberg, Mia, Naucler, Gisela, Kersten, Christian, Vistisen, Kirsten, Lindh, Birgitta, Glimelius, Bengt

“…Abstract only 3538 Background: NORDIC 7.5 is a multi-center phase II trial of Nordic FLOX plus biweekly C followed by maintenance C in first-line treatment of…”
Get full text

Oxidative DNA damage estimated by 8-hydroxydeoxyguanosine excretion in humans: influence of smoking, gender and body mass index by Loft, S, Vistisen, K, Ewertz, M, Tjønneland, A, Overvad, K, Poulsen, H E

“…Oxidative DNA damage may be implicated in ageing, carcinogenesis and other degenerative diseases. Oxidative DNA damage can be assessed in humans in vivo from…”
Get more information